廣告
香港股市 將收市,收市時間:6 小時 9 分鐘
  • 恒指

    17,878.64
    -63.14 (-0.35%)
     
  • 國指

    6,356.31
    -18.35 (-0.29%)
     
  • 上證綜指

    3,018.94
    -13.69 (-0.45%)
     
  • 滬深300

    3,523.03
    -18.50 (-0.52%)
     
  • 美元

    7.8094
    -0.0010 (-0.01%)
     
  • 人民幣

    0.9283
    -0.0001 (-0.01%)
     
  • 道指

    38,589.16
    -57.94 (-0.15%)
     
  • 標普 500

    5,431.60
    -2.14 (-0.04%)
     
  • 納指

    17,688.88
    +21.28 (+0.12%)
     
  • 日圓

    0.0493
    -0.0001 (-0.10%)
     
  • 歐元

    8.3563
    -0.0048 (-0.06%)
     
  • 英鎊

    9.9020
    -0.0040 (-0.04%)
     
  • 紐約期油

    78.29
    -0.16 (-0.20%)
     
  • 金價

    2,341.90
    -7.20 (-0.31%)
     
  • Bitcoin

    66,433.10
    +311.46 (+0.47%)
     
  • CMC Crypto 200

    1,408.37
    -9.50 (-0.67%)
     

Biogen in up to $1.8 billion deal as rare diseases take center stage

Illustration shows Biogen logo

(Reuters) -Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its older multiple sclerosis drugs face tepid demand due to rising competition.

Human Immunology's (HI-Bio) felzartamab has completed mid-stage studies for a type of kidney disease called primary membranous nephropathy, and in patients with a disease where the immune system makes antibodies that damage their transplanted organ.

The San Francisco-based company is also testing the therapy in patients with another chronic kidney disease known as IgA nephropathy. The therapy developer plans to conduct late-stage trials.

Since Christopher Viehbacher took the helm in late 2022, Biogen has acquired rare disease drugmaker Reata for $6.5 billion, abandoned its controversial Alzheimer's disease drug Aduhelm and cut jobs.

廣告

The company is now counting on newer medicines such as a second approved Alzheimer's drug Leqembi, developed with Japanese partner Eisai, as well as Reata's Skyclarys to help drive growth.

The deal consists of $1.15 billion in upfront and up to $650 million in potential payments if felzartamab achieves certain development milestones.

The deal is expected to close in the third quarter, the companies said on Wednesday. HI-Bio is backed by investors such as biotech-focused ARCH Venture Partners and Monograph Capital.

(Reporting by Manas Mishra and Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila)